Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE)-- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Terahertz devices have applications in biomedicine, imaging, sensing, and communication. However, rapidly tuning their ...
A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results